A team led by researchers from Weill Cornell Medicine has succeeded in isolating and growing authentic reservoir clones (ARCs), the elusive one-in-a-million HIV-infected T cells that persist despite antiviral drugs. These cells integrate viral DNA into their genome and stay dormant, dodging immune detection and enabling viral rebound if therapy stops. Published in Nature, the findings show most ARCs gradually succumb to sustained attack by cytotoxic T lymphocytes (CTLs), though a resistant subset survives via latency combined with death resistance.

“For decades, we have known that HIV hides in long-lived immune cells called T cells. But, we have not been able to study those extremely rare—one in a million—cells,” said senior author Brad Jones. Co-led by Isabella Ferreira and Alberto Herrera from Jones’s lab, the researchers extracted ARCs from study participants and cultured them for analysis. “We discovered that finding a needle in a haystack is not always impossible,” Jones noted. “It just takes a team effort.”

In the lab, few ARCs produced new virus particles, and reactivation was challenging, reflecting their in-body behavior. When paired long-term with potent CTLs—the body’s key HIV killers—most clones eroded over time, as immune cells caught brief HIV expression windows. Still, some persisted through proliferation rounds or quiescence under heavy pressure. “The problem is not only latency,” Dr. Jones said. “It is latency plus resistance to death.”

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

The team tested deferoxamine, an FDA-approved drug, which ramped up oxidative stress in resistant cells, allowing CTLs to kill them more readily. “By sensitizing cells to oxidative stress, we were able to restore the cell’s susceptibility to immune cell attacks,” Jones explained, suggesting viable combination strategies ahead.

Now refining ARC culturing methods, the group plans to share cells or techniques with other labs and compile a full catalog of survival mechanisms to pinpoint treatment targets. “If we can properly arm the immune system to kill those cells when they are exposed, we may be able to tip the balance towards eliminating the reservoirs and curing infection,” Jones concluded.